A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Trial Profile

A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs APX 001 (Primary)
  • Indications Aspergillosis; Candidiasis; Mycoses
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 31 Jul 2017 Status changed from recruiting to completed.
    • 12 Sep 2016 Status changed from planning to recruiting according to an Amplyx Pharmaceuticals media release.
    • 12 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top